Latest Cannabis Pharmaceuticals News

Cann Group Limited has reported its first-ever free cash flow positive quarter, following a significant debt restructuring and a $9 million capital raise. Despite a softer quarterly revenue, the company is advancing new product launches and export partnerships, positioning itself for growth.

Cann Group Limited reminds eligible shareholders that its Share Purchase Plan (SPP) closes today, offering new shares at a discount plus free attaching options, pending shareholder approval.

Cann Group Limited has opened a $6.5 million Share Purchase Plan (SPP) alongside a placement, offering shareholders discounted shares with attaching options as it targets significant revenue growth in FY26.

Cann Group Limited has extended the expiry of its National Australia Bank debt facilities by one year to October 2025, maintaining current terms while exploring long-term refinancing options.

Cann Group Limited has reported its first-ever EBITDA-positive month in August 2025, driven by strong B2B flower sales and disciplined cost management. The company is advancing export negotiations in Europe and preparing to launch a new Botanitech product range.

Neurotech International reported a 23% revenue drop and a doubling of its net loss to $10.6 million for FY25, driven by reduced R&D grants and high development costs. Despite financial pressures, the company marked significant clinical and regulatory progress for its NTI164 cannabinoid therapy.

Bod Science reports a solid net cash inflow of $858,000 in Q4 FY2025, driven by R&D incentives and Biortica funding, while awaiting shareholder approval to complete a key acquisition.

Althea Group Holdings has agreed to sell its pharmaceutical assets to Tasmanian Botanics, enabling a strategic pivot towards the booming North American THC-infused beverage market.

Althea Group Holdings has obtained Federal Court orders confirming the validity of past share sales despite previous failures to lodge required Cleansing Notices, paving the way for the reinstatement of its shares to trading.

Bod Science Limited reports a modest net cash inflow of $51,000 for Q2 FY2025, supported by increased customer receipts and intellectual property sales, while navigating a complex Deed of Company Arrangement and pending acquisition.